Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Lewy body dementia

Topic: Brain proteins, microglia and lab models

Plain-language summary

DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson’s disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring. DOPA decarboxylase (DDC) in cerebrospinal fluid has great diagnostic potential for Lewy body disorders. Here, the authors report limited diagnostic potential of plasma DDC and a strong association with dopaminergic treatment.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 71 participants. Plasma DDC was not altered between different Lewy body disorders and other disease groups or controls in absence of treatment, and levels increased with higher dosages of dopaminergic treatment. Plasma DDC is of limited use as a diagnostic biomarker for Lewy body disorders but could be valuable for treatment monitoring.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Bolsewig, K., Willemse, E. A., Sánchez‐Juan, P., Rábano, A., Martinez-Castillo, M., Doecke, J. D., et al. (2025). Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nature Communications. https://doi.org/10.1038/s41467-025-56293-z

Vancouver

Bolsewig K, Willemse EA, Sánchez‐Juan P, Rábano A, Martinez-Castillo M, Doecke JD, et al. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nature Communications. 2025. doi:10.1038/s41467-025-56293-z. PMID: 39881147.

BibTeX

@article{bolsewig2025-39881147,
  author  = {Bolsewig, Katharina and Willemse, Eline A.J. and Sánchez‐Juan, Pascual and Rábano, Alberto and Martinez-Castillo, Minerva and Doecke, James D. and Bellomo, Giovanni and Vermunt, Lisa and others},
  title   = {{Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment}},
  journal = {Nature Communications},
  year    = {2025},
  doi     = {10.1038/s41467-025-56293-z},
  pmid    = {39881147},
  url     = {https://doi.org/10.1038/s41467-025-56293-z}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Plasma DDC was not altered between different Lewy body disorders and other disease groups or controls in absence of treatment, and levels increased with higher dosages of dopaminergic treatment. Plasma DDC is of limited use as a diagnostic biomarker for Lewy body disorders but could be valuable for treatment monitoring.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 63 of 100.63 of 100 points earned37 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Communications)
Journal's citation record 4 / 4 Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 71 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 20 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 6.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 11.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 2 other studies in this library
Still being cited 2 / 4 Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Marta del Campo: h-index 24 (OpenAlex, whole career)
Institution's track record 1 / 3 The University of Melbourne: institution h-index 1,342 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 26 institution(s) in 8 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39881147)
Free to read 2 / 2 Free to read
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Lewy body dementia from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Lewy body dementia

See all studies in Lewy body dementia →